Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor

Journal of Cellular and Molecular Medicine

Volumn 20, Issue 10, 2016, Pages 1829-1839

  Corrado, Chiara ^a   Saieva, Laura ^a   Raimondo, Stefania ^a   Santoro, Alessandra ^b   De Leo, Giacomo ^a   Alessandro, Riccardo ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b AO Ospedali Riuniti Villa Sofia Cervello   (Italy)

Author keywords

chronic myeloid leukaemia; epidermal growth factor receptor; exosomes; interleukin 8; SNAIL

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; INTERLEUKIN 8; TRANSCRIPTION FACTOR SNAIL; AMPHIREGULIN; LIPOCORTIN 2; MESSENGER RNA; SMALL INTERFERING RNA;

ARTICLE; BONE MARROW MICROENVIRONMENT; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING; BONE MARROW CELL; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; STROMA CELL; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

AMPHIREGULIN; ANNEXIN A2; BONE MARROW CELLS; CELL ADHESION; CELL LINE, TUMOR; CELLULAR MICROENVIRONMENT; EXOSOMES; HUMANS; INTERLEUKIN-8; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MATRIX METALLOPROTEINASE 9; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; RNA, SMALL INTERFERING; SNAIL FAMILY TRANSCRIPTION FACTORS; STROMAL CELLS;

EID: 84971311450     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12873     Document Type: Article

References (43)

1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243: 290–3.
2. Sonoyama J, Matsumura I, Ezoe S, et al. Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem. 2002; 277: 8076–82.
3. Druker B, Sawyers C, Kantarjian H, et al. Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344: 1038–42.
4. Agarwal A, Fleischman AG, Petersen CL, et al. Effects of plerixafor in combination with BCR–ABL kinase inhibition in a murine model of CML. Blood. 2012; 120: 2658–68.
5. Vianello F, Villanova F, Tisato V, et al. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica. 2010; 95: 1081–9.
6. Seke Etet PF, Vecchio L, Nwabo Kamdje AH. Signaling pathways in chronic myeloid leukemia and leukemic stem cell maintenance: key role of stromal microenvironment. Cell Signal 2012; 24:1883–8.
7. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18: 883–91.
8. Huan J, Hornick NI, Skinner AM, et al. RNA trafficking by acute myeloid leukemia exosomes. Cancer Res. 2013; 73: 918–29.
9. Corrado C, Raimondo S, Chiesi A, et al. Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications. Int J Mol Sci. 2013; 14: 5338–66.
10. Corrado C, Flugy AM, Taverna S, et al. Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis. PLoS ONE. 2012; 7: e42310.
11. Taverna S, Flugy A, Saieva L, et al. Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis. Int J Cancer. 2012; 130: 2033–43.
12. Corrado C, Raimondo S, Saieva L, et al. Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an Interleukin 8-dependent survival of leukemia cells. Cancer Lett. 2014; 348: 71–6.
13. Raimondo S, Saieva L, Corrado C, et al. Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism. Cell Commun Signal. 2015; 13: 8.
14. Kerpedjieva SS, Kim DS, Barbeau DJ, et al. EGFR ligands drive multipotential stromal cells to produce multiple growth factors and cytokines via early growth response-1. Stem Cells Dev. 2012; 21: 2541–51.
15. Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal. 2005; 17: 1183–93.
16. Wilson KJ, Mill C, Lambert S, et al. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors. 2012; 30: 107–16.
17. Castillo J, Erroba E, Perugorría MJ, et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res. 2006; 66: 6129–38.
18. Willmarth NE, Ethier SP. Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. J Biol Chem. 2006; 281: 37728–37.
19. Singh B, Coffey RJ. Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells. Annu Rev Physiol. 2014; 76: 275–300.
20. Higginbotham JN, Demory Beckler M, Gephart JD, et al. Amphiregulin exosomes increase cancer cell invasion. Curr Biol. 2011; 21: 779–86.
21. Busser B, Sancey L, Brambilla E, et al. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta. 2011; 1816: 119–31.
22. So WK, Fan Q, Lau MT, et al. Amphiregulin induces human cancer cell invasion by down-regulating E-cadherin expression. FEBS Lett. 2014; 588: 3998–4007.
23. D'Souza S, Kurihara N, Shiozawa Y, et al. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood. 2012; 119: 1888–96.
24. Thery C, Amigorena S, Raposo G, et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006; Unit 3.22. 1–3.22.29.
25. Gan Y, Shi C, Inge L, et al. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene. 2010; 29: 4947–58.
26. Liu ZC, Chen XH, Song HX, et al. Snail regulated by PKC/GSK-3β pathway is crucial for EGF-induced epithelial-mesenchymal transition (EMT) of cancer cells. Cell Tissue Res. 2014; 358: 491–502.
27. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006; 1: 119–50.
28. De Luca A, Gallo M, Aldinucci D, et al. Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J Cell Physiol. 2011; 226: 2131–8.
29. Tamama K, Kawasaki H, Wells A. Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC. J Biomed Biotechnol. 2010; 2010: 795385.
30. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev. 2005; 15: 97–101.
31. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9: 239–52.
32. Batlle R, Alba-Castellón L, Loubat-Casanovas J, et al. Snail1 controls TGF-β responsiveness and differentiation of mesenchymal stem cells. Oncogene. 2013; 32: 3381–9.
33. Hwang WL, Yang MH, Tsai ML, et al. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology. 2011; 141: 279–91.
34. Zhang X, Liu S, Guo C, et al. The association of annexin A2 and cancers. Clin Transl Oncol. 2012; 14: 634–40.
35. Lokman NA, Ween MP, Oehler MK, et al. The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron. 2011; 4: 199–208.
36. Martin-Belmonte F, Gassama A, Datta A, et al. PTEN-mediated apical segregation of phosphoinositides controls epithelial morphogenesis through Cdc42. Cell. 2007; 128: 383–97.
37. Burkart A, Samii B, Corvera S, et al. Regulation of the SHP-2 tyrosine phosphatase by a novel cholesterol- and cell confluence-dependent mechanism. J Biol Chem. 2003; 278: 18360–7.
38. Grewal T, Enrich C. Annexins — modulators of EGF receptor signalling and trafficking. Cell Signal. 2009; 21: 847–58.
39. Shiozawa Y, Havens AM, Jung Y, et al. Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem. 2008; 105: 370–80.
40. Jung Y, Wang J, Lee E, et al. Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. Mol Cancer Res. 2015; 13: 197–207.
41. Seckinger A, Meissner T, Moreaux J, et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood. 2012; 120: 1087–94.
42. Esposito I, Penzel R, Chaib-Harrireche M, et al. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol. 2006; 208: 673–85.
43. Sharma MR, Koltowski L, Ownbey RT, et al. Angiogenesis associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol. 2006; 81: 146–56.